Details for Patent: 8,901,176
✉ Email this page to a colleague
Title: | Methods for treatment of Parkinson's disease |
Abstract: | New uses of safinamide, safinamide derivatives and MAO-B inhibitors in novel types of treatment for Parkinson's Disease are described. More specifically, the invention relates to methods for treating Parkinson's Disease through the administration of safinamide, a safinamide derivative, or a MAO-B inhibitor, in combination with other Parkinson's Disease agents or treatments, such as levodopa/PDI or dopamine agonists. |
Inventor(s): | Fariello; Ruggero (Luino, IT), Cattaneo; Carlo (Milan, IT), Salvati; Patricia (Arese, IT), Benatti; Luca (S. Maurizio al Lambro, IT) |
Assignee: | Newron Pharmaceuticals, S.P.A. (Bresso, IT) |
Filing Date: | Aug 24, 2012 |
Application Number: | 13/594,621 |
Claims: | 1. In a method of treating idiopathic Parkinson's disease in a patient receiving a stable dose of dopamine agonist, the improvement comprising: concurrently administering a therapeutically effective amount of safinamide, or a pharmaceutically acceptable salt thereof, on an oral daily dosage schedule, while maintaining the patient on a stable dose of the single dopamine agonist. 2. A method of treating idiopathic Parkinson's Disease, comprising: administering a therapeutically effective stable dose of a dopamine agonist; and concurrently administering a therapeutically effective amount of safinamide, or a pharmaceutically acceptable salt thereof, on an oral daily dosage schedule. 3. The method of claim 1 or claim 2, wherein safinamide, or pharmaceutically acceptable salt thereof, is administered for at least 12 weeks. 4. The method of claim 1 or claim 2, wherein safinamide, or pharmaceutically acceptable salt thereof, is administered once daily. 5. The method of claim 1 or claim 2, wherein safinamide is administered as the methanesulfonate salt. 6. The method of claim 1 or claim 2, wherein the single dopamine agonist is selected from the group consisting of: ropinirole, pramipexole, and rotigotine. |